Core Insights - JD Health and Hangzhou Minsheng Health Pharmaceutical Co., Ltd. signed a strategic cooperation agreement to explore patient-centered health management solutions covering the entire disease cycle [1] - The partnership aims to leverage each other's strengths in branding, products, channels, technology, and professional services to enhance the accessibility and trust in high-quality health products and services for patients [1] Group 1: Strategic Cooperation - JD Health and Hangzhou Minsheng Health Pharmaceutical will collaborate on drug development, digital marketing, and patient education to accelerate the distribution of quality health products nationwide [1] - The CEO of Hangzhou Minsheng Health Pharmaceutical emphasized the importance of JD Health's omnichannel layout and professional medical service resources in enhancing patient access to quality health resources [1] Group 2: New Product Launch - Hangzhou Minsheng Health Pharmaceutical launched a new smoking cessation drug, Varenicline Tartrate Tablets (brand name: Minsheng Lesuke®), on JD Health, featuring a 0.5mg mini tablet design for easier dosage adjustment [2] - The packaging utilizes advanced double aluminum sealing technology to ensure drug stability, and the tablet includes easy-to-tear markings for daily dosage management [2] Group 3: Industry Development - JD Health is committed to deepening industry cooperation and enhancing the scientific smoking cessation ecosystem, aiming to provide high-quality smoking cessation products and promote scientific cessation methods [3] - The company has developed a comprehensive solution for the launch of new smoking cessation drugs and aims to address common pain points faced by smoking cessation users through various initiatives [2][3]
京东健康与杭州民生健康药业达成战略合作 线上首发戒烟新药民生乐速克®